Renal cell carcinoma (RCC) accounts for approximately 3 % of adult malignancies and 90-95 % of neoplasms arising from the kidney.
This article will outline the current standard of care in the treatment in mRCC with a perspective on immunotherapy in the era of targeted therapy, and review research into combined and targeted therapies and evolving therapeutic strategies. Additionally, it will discuss further evolution of paradigms, with an emphasis on tailoring therapies and achieving complete response.
Current Treatment Pathways
It is important to be aware that mRCC is a heterogeneous disease and that no single-standard treatment algorithm should be applied to all patients. Initially, when patients present with mRCC, they are evaluated for possible cytoreductive nephrectomy and metastasectomy. If metastatic disease persists following these treatments, then systemic therapy must be considered. Initial treatment involves observation in selected cases, locally directed therapies including resection, or medical treatment. The latter involves one of the approved agents (including cytokines and antiangiogenic targeted therapies -see Table 2 It is important to set goals in terms of stabilization and improvement expected from first-line treatment, and involve the patient in the therapeutic decisions regarding when to move on to the next treatment stage. Choices are wider for second-line treatment and beyond, any of the targeted agents being possible options. Everolimus and axitinib have demonstrated efficacy in randomized trials that were specifically highlighting the population with prior TKI treatment targeting the vascular endothelial growth factor (VEGF) pathway. 11, 12 It is plain that there are potentially multiple lines of therapy, and the choice can be daunting.
Immunotherapy
When considering a new paradigm in the treatment of mRCC, the focus should be on optimizing cure fraction -i.e., complete response and remission. The rise in popularity of targeted agents has resulted in a decline in the use of immunotherapy, such as high-dose IL-2, because it is effective only in a minority of patients and is associated with severe acute toxicities. 13, 14 The new agents provide benefits in terms of PFS;
however, high-dose IL-2 remains the agent with proven efficacy in producing complete remission in patients with mRCC.
In 1992, high-dose IL-2 was approved by the FDA for the treatment of patients with mRCC based on data from seven Phase II trials. 15 Following this, a randomized trial compared low-dose and high-dose IL-2 in mRCC. The response rates in patients treated with high-dose IL-2 were twice as high as those seen in patients treated with low-dose IL-2 or subcutaneous IL-2 alone. In addition, many more durable complete responses were seen in the high-dose IL-2 arms, many of these responses lasting more than a decade in duration. 16 A subsequent Phase III trial (n=192) found that high-dose IL-2 induced a response rate of 23.2 % and a median survival of 17.5 months in patients with mRCC, and concluded that it should remain the preferred treatment in selected patients. 17 Given that high-dose IL-2 is currently the only approved therapy that can induce such durable complete responses, it should be considered more often as first-line therapy. However, it is currently not possible to identify patients who will benefit from it. The importance of assessing patient suitability is illustrated in a recent case series of 72 patients with RCC given high-dose IL-2 as first-line treatment. The overall response rate, irrespective of histology, was 27 %; however, following the stratification of patients according to histology, the response rate was 52 % in the subgroup of patients with favorable histologic features.
Among all patients with a favorable histology, including those identified retrospectively, the combined response rate was 49 %, 25 % achieved complete remission and responses appeared to be durable. 18 
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Worse prognosis is associated with three or more of the following:
• corrected serum calcium of more than 10 mg/dl
• more than two sites of metastatic disease
• an interval of less than one year between the original diagnosis and the start of systemic therapy
• hemoglobin level less than the lower limit of normal
• lactic dehydrogenase level more than 1.5 times the normal
• Karnofsky performance status score ≤70
Source: Hudes et al., 2007. 37 Treatment with high-dose IL-2 should be avoided in patients with severe cardiac, lung, or kidney dysfunction. 21 Surprisingly, a Phase III trial comparing high-dose IL-2 with subcutaneous IL-2 plus IFN-α found a significant survival benefit with high-dose IL-2 in a subset of patients with liver and bone metastases (p=0.001) as well as in patients with primary tumors in place (p=0.04) (see Figure 1 ). 17 However, these individuals still did poorly compared with the overall study population, and are unlikely to form a major group from which to identify patients who would benefit from high-dose IL-2. Histology studies have found the greatest response to IL-2 in clear cell histology patients with more than 50 % alveolar and no granular or papillary features. 22, 23 A lack of retroperitoneal lymphadenopathy has also emerged as a prognostic indicator of survival in IL-2 therapy.
24
A biomarker with the ability to predict which patients would benefit from IL-2 before any treatment is initiated would be valuable for maximizing the advantage of this therapy, identifying those with better response potential and directing those with less chance to benefit to other initial treatments. However, finding such a biomarker has been elusive. C-reactive protein, an acute-phase protein synthesized as part of the systemic inflammatory response, showed promise as a potential biomarker in early studies, 25, 26 but has not, to date, been found to be of clinical use. Carbonic anhydrase IX (CAIX) is a transmembrane member of the carbonic anhydrase family and is thought to play a role in cell proliferation in response to hypoxic conditions. CAIX is not expressed in healthy renal tissue but is expressed in most clear cell RCCs, and was evaluated as a potential biomarker of response to IL-2. 27 However, recent results from a non-randomized Phase II trial found a response rate to IL-2 of 30 % in patients with clear cell RCC but did not find significant associations between the response to IL-2 and CAIX. Another consideration related to IL-2 treatment is the fact that some people are not able to take time off work to receive a treatment that requires hospitalization. However, the short-term loss of revenue should be balanced against the long-term health gain -if IL-2 therapy was to be successful, the person would not need lifelong therapy.
Targeted Therapies
As a result of the greater understanding of the molecular mechanisms underlying RCC angiogenesis and growth, several new agents targeting relevant cellular signaling pathways were developed in the last decade (see Figure 2) . Several have demonstrated significant efficacy in the treatment of mRCC (see Table 3 ) in subpopulations much less narrowly defined than for IL-2 treatment, and these medications are the core of current treatment algorithms.
The oral multikinase inhibitors inhibit signaling by multiple targets including vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors. Sorafenib was the first oral multikinase inhibitor approved for use in mRCC. 30, 31 Sorafenib is a commonly used agent for second-line treatment of mRCC after Other therapeutic agents target mTOR, which is a serine/threonine kinase and a central component of the signaling pathways governing cell proliferation, survival, metabolism, angiogenesis, and apoptosis. The FDA has approved two mTOR inhibitors for kidney cancer therapy.
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Temsirolimus induced an improvement in OS in mRCC patients who had features indicative of a poor prognosis 37 and is a recommended first-line treatment in such patients. 4 Everolimus is indicated for use following failure of treatment with sorafenib or sunitinib. However, unlike high-dose IL-2, which can achieve a durable complete response, that type of response has not been seen in the randomized trials investigating targeted therapies, but only described in case reports.
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The selection of a targeted agent in mRCC should take into account disease status, histology, and patient status. In symptomatic patients and in patients with large tumor burden, an agent such as sunitinib is indicated because of the rapid tumor shrinkage often observed with this drug. In patients who have multiple (more than two) prognostic risk factors, temsirolimus is preferred, considering that the pivotal temsirolimus trial demonstrated a survival benefit in this specific patient group. Sorafenib and everolimus have been reported to be well tolerated in elderly patients in first-and second-line settings. 40 In asymptomatic patients, especially those with predominantly lung metastases, bevacizumab plus IFN-α is an option, because it has been observed that a benefit from IFN-α is more likely in this patient population. 41 However, current guidelines have fundamental limitations when applied to patients from the general, non-study population: treatments for mRCC have not usually been evaluated specifically for patients with comorbidities and/or who are receiving several medications. 
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Circulating factors may also provide insights into determinants of response and resistance. 48 A coordinated effort is required to bring these assays to the point of testing in prospective trials.
While the success of targeted therapies established a new standard of care in the treatment of mRCC, there remains a profound need for new agents or combinations of treatments that will improve clinical activity while carrying a reduced risk of treatment-associated toxicities. With the current agents, side effects are frequent -although virtually all can be managed effectively. 49 The area of targeted therapies is rapidly changing, as new agents are introduced, supported by evidence from randomized controlled trials; however, few data directly compare newer versus more established agents or specific drug selection strategies.
Combining and Sequencing Therapies
An active area of current research is to determine better combinations Increased toxicities remain a barrier to the success of combinations of targeted therapies. 51 The combination of sorafenib and bevacizumab was evaluated in a Phase I trial and resulted in an unexpected level of toxicity at lower doses. 52 A Phase I trial of sunitinib plus temsirolimus was terminated due to significant toxicity observed at low starting doses of both drugs. 53 A Phase I trial of tivozanib plus temsirolimus found that the combination was tolerable at standard doses of both agents, but the relative response rate and durability were not evaluated. 54 Immunotherapy may play a role in combined therapeutic approaches.
Several combinations of IL-2, IFN-α, and other chemotherapeutic agents such as 5-fluorouracil have been tried over the years. 55 These have, in some cases, resulted in apparent improvements in outcomes, but
have not been shown in a randomized setting to give clinical benefits that would outweigh the greater levels of toxicity. In a Phase III trial, the combination of subcutaneous IL-2 and IFN-α was not more effective than high-dose IL-2 alone. 17 In another open-label randomized trial, the combination of IFN-α and IL-2 did not improve OS or PFS compared with IFN-α alone, but did induce long remissions in a small number of patients. No significant increase in toxicity was observed with this combination. 56 Results from a Phase II trial incorporating bevacizumab with low-dose IL-2 suggest that this combination has modest clinical activity in mRCC and does not confer additional toxicity. 57 Sorafenib plus low-dose IFN-α was found to be active and well tolerated in several Phase II trials; 58, 59 however, the addition of low-dose IFN did not appear to improve response rate or PFS in a randomized study. 59 In addition, recently published data from a Phase II trial found that the combination of sorafenib and IL-2 did not demonstrate improved efficacy compared with sorafenib alone. 60 Given the toxicity issues associated with combination therapies, sequential therapy remains the standard of care and current research aims to determine an optimum sequence of targeted agents.
Currently, the only agents with specific, Phase III trial-based recommendations for use after primary VEGF-targeting TKI therapy are everolimus and axitinib, 4 although any of the targeted agents can be considered after cytokine therapy. Several clinical trials are underway to evaluate the optimal combination and sequencing of targeted therapies; these trials are summarized in Figure 3 . A recent review concluded that the optimal sequence may vary between patients according to comorbid conditions and/or disease stage.
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Cytoreductive Nephrectomy
Cytoreductive nephrectomy has been shown to improve OS in mRCC patients. 62 Following the introduction of targeted therapies, it is unclear to what extent, when such therapies are used, there is still as consistently a benefit from cytoreductive nephrectomy. Ongoing randomized prospective trials will address this question. However, the majority of patients in the sunitinib and sorafenib Phase III trials underwent nephrectomy as part of their prior treatment 30, 32 and, in a retrospective
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study, cytoreductive nephrectomy was independently associated with a prolonged OS in patients with RCC treated with VEGF-targeting agents. 63 As a separate issue, regarding symptoms as opposed to survival, cytoreductive nephrectomy may be offered to patients experiencing symptoms related to the primary tumor, such as pain caused by the kidney mass, intractable hematuria, erythrocytosis, uncontrolled hypertension, or persistent hypercalcemia, 64 or to individuals with a performance status of 0 or 1 and resectable primary tumor meeting the eligibility criteria of the upfront nephrectomy trials reported by Flanigan et al.
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Emerging Agents and Novel Treatment Approaches
In a Phase III clinical trial of tivozanib, a small molecule that inhibits VEGFR, this targeted agent completed accrual and PFS data were reported. Tivozanib was shown to extend PFS in treatment-naive mRCC patients compared with sorafenib (median PFS of 12.7 months versus 9.1 months, respectively) and is being considered for FDA approval. • WX-G250, a monoclonal antibody that binds to CAIX; 75 • agents that inhibit tumor-induced immunosuppression, such as transforming growth factor β antibody and purified antihuman CD274 (PDL1) antibody; 76 • agents that activate T cells (e.g., CD-137 antibody and IL-21; 77 and
• agents that activate dendritic cells (e.g., toll-like receptor agonists). 78 Interest in vaccines for mRCC remains high. IMA901 is a therapeutic cancer vaccine based on the selection of naturally presented tumor-associated peptides. A Phase II study found that IMA901 is safe, well tolerated, and immunogenic, and OS compared favorably with currently approved drugs. 79 A Phase III trial is underway that looks at sunitinib therapy with or without the addition of a peptide vaccine, granulocyte macrophage colony stimulating factor, and cyclophosphamide pre-treatment. found to be well tolerated and without major side effects. 83 For similar reasons, combinations of sunitinib with checkpoint inhibitors, including anti-CTLA-4 and anti-PD1, may be of therapeutic value.
It is possible that the cure fraction of existing cytokine therapies could be increased if they were to be combined with these novel immunomodulatory agents. Potential studies include combinations of IL-2 and checkpoint inhibitors. These trials need to be properly controlled in order to understand the role of each agent, and performed in the context of robust immune monitoring in order to assess whether changes in T-cell response are achieved, whether these changes are linked to clinical benefit, and whether one can identify subpopulations of patients who should receive these combinations.
Implementation of Tailored Strategies in Treatment Algorithms
The implementation of more tailored strategies in treatment algorithms could potentially improve outcomes for patients with mRCC in two ways.
One would be to achieve durable complete responses, and the other would be to have more durability within the targeted drug paradigm.
Ongoing research to characterize molecular components of both tumor and host should allow the categorization of patients according to sensitivities to particular agents or combinations/sequences of agents.
The ultimate aim would be a relatively simple and non-invasive test to direct the choice of a particular drug, drug combination or drug sequence, but achieving this goal will require continued investment in clinical trials and research. Future clinical trials need to be designed to capture material that permits analysis, as promising tests are developed. Collaborative efforts between industry, academic institutions, and funding agencies will help to set up these clinical trials.
Summary and Concluding Remarks
Targeted therapies have largely overtaken immunotherapy as the standard of care in mRCC, representing a great advance for many patients. Less than 10 years ago, the median survival among patients with mRCC was under a year. New developments in targeted therapies and drug sequencing have significantly increased median survival. As more data regarding predictive biomarkers of response to treatment, new targeted agents, and optimal drug combinations and sequences become identifiable, researchers will move closer to the goal of having tailored strategies that can provide maximum efficacy with manageable toxicity.
However, it is important to remember that a subset of patients shows a complete and durable response to IL-2, and ongoing efforts are being 
